32 C-reactive protein (CRP) as a prognostic biomarker in advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Results from a multi-center international observational study
Main Authors: | Abdul Rafeh Naqash, Mahvish Muzaffar, Shravanti Macherla, Alessio Cortellini, James Clark, Emma Mi, Sanna Livanainen, Daria Gramenitskaya, Kevin O’Brien, Jussi Koivunen, Sweta Jonnalagadda, Shanker Polsani, Rahim Jiwani, Nitika Sharma, Chipman Stroud, Paul Walker, David Pinato |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer
by: Shravanti Macherla, et al.
Published: (2018-11-01) -
Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition
by: Abdul Rafeh Naqash, et al.
Published: (2019-07-01) -
Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection
by: Sanna Iivanainen, et al.
Published: (2020-01-01) -
Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors
by: Sanna Iivanainen, et al.
Published: (2019-07-01) -
Antibiotic therapy and outcome from immune-checkpoint inhibitors
by: David J. Pinato, et al.
Published: (2019-11-01)